within Pharmacolibrary.Drugs.ATC.J;

model J07AM52
  extends Pharmacokinetic.Models.PK_1C(
    weight         = 70,
    F              = 1,
    Cl             = 3.3333333333333333e-06,
    adminDuration  = 600,
    adminMass      = 500 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.005,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J07AM52</td></tr><td>route:</td><td>intramuscular</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>A combination product containing tetanus toxoid, a vaccine used to induce active immunity against tetanus, together with tetanus immunoglobulin, which provides passive immediate immunity to tetanus. It is typically used for post-exposure prophylaxis in individuals with risk of tetanus infection, especially when immunization status is uncertain or incomplete. Both components are approved and widely used for prevention of tetanus.</p><h4>Pharmacokinetics</h4><p>Estimated pharmacokinetic parameters for healthy adults; no direct pharmacokinetic studies or publications were found for the combination product.</p><h4>References</h4><ol><li><p>Gupta, PN, et al., &amp; Vyas, SP (2005). Tetanus toxoid-loaded transfersomes for topical immunization. <i>The Journal of pharmacy and pharmacology</i> 57(3) 295–301. DOI:<a href=&quot;https://doi.org/10.1211/0022357055515&quot;>10.1211/0022357055515</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/15807984/&quot;>https://pubmed.ncbi.nlm.nih.gov/15807984</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J07AM52;
